ODM-201

$ 2.00 /1kg

Min. Order1kg
Purity99%
Cas No1297538-32-9
Supply Ability100kg
Update time2019-07-06

career henan chemical co

6YR

China

Chemical Properties

Product Name	ODM-201
CAS No	1297538-32-9
EC-No
Min. Order	1kg
Purity	99%
Supply Ability	100kg
Release date	2019/07/06

ODM-201 Basic information

Product Name:	ODM-201
Synonyms:	ODM-201;BAY-1841788;N-[(1S)-2-[3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl]-1-methylethyl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide;Darolutamide;N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide;Darolutamide (ODM-201)
CAS:	1297538-32-9
MF:	C19H19ClN6O2
MW:	398.84616
EINECS:	-0
Product Categories:
Mol File:	1297538-32-9.mol

ODM-201 Chemical Properties

Safety Information

MSDS Information

ODM-201 Usage And Synthesis

Description

ODM-201 is a novel androgen receptor (AR) inhibit designed to inhibit the growth of prostate cancer cells through binding to the AR to inhibit the testosterone-induced AR nuclear translocation. It is particularly used in patients with progressive metastatic castration-resistant prostate cancer. It is effective in inhibiting the activity of some mutant ARs emerging during antiandrogen therapies, including the F876L mutation version which is resistant to enzalutamide and ARN-509 (the second-generation antiandrogens).Therefore, it has potential to overcome the resistance issue occurring upon AR-targeted therapies.

References

Moilanen, Anu Maarit, et al. "Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies." Sci Rep 5.2(2015):12007. Fizazi, Karim, et al. "ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: Preclinical and phase I data." Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of 2013. Fizazi, K, et al. "Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial." Lancet Oncology 5.9(2014):975-85.

Company Profile Introduction

Recommended supplier

Send Inquriy

ODM-201

Company Profile Introduction

You may like

Recommended supplier